Shares of Royal Philips NV (PHG) plummeted 13.18% on Wednesday, following the Dutch healthcare technology company's underwhelming fourth-quarter results and weaker-than-expected outlook for 2025, marred by persistent weakness in China.
For the fourth quarter of 2024, Philips reported an adjusted earnings per share of €0.51, missing analysts' expectations of €0.57. Revenue came in at €5.044 billion, slightly below the consensus estimate of €5.1 billion. The company swung to a net loss of €334 million, mainly due to a €449 million tax charge.
The disappointing performance was primarily driven by a double-digit decline in sales in China, where subdued consumer sentiment and anti-graft measures in the healthcare sector continue to weigh on demand. For 2025, Philips forecasts a mid- to high-single-digit decline in China sales, which accounts for around 10% of the company's total revenue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.